CRBU
vs
S&P 500
CRBU
S&P 500
Over the past 12 months, CRBU has underperformed S&P 500, delivering a return of -12% compared to the S&P 500's +13% growth.
Stocks Performance
CRBU vs S&P 500
Performance Gap
CRBU vs S&P 500
Performance By Year
CRBU vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Caribou Biosciences Inc
Glance View
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
